7th Annual Conference on Stem Cell and Regenerative Medicine Aug 04-05, 2016 Manchester , UK

Denis Barritault graduated in Physics, completed his PhD in biochemistry in Paris University. Post doctoral in molecular immunology at Pasteur Institute and NYU as NIH Fogarty Fellow he joined INSERM unit in Paris as developmental biologist. He made the first description and patents of FGF extracted from retina in 1979 and 82 as skin and cornea healing agent, became full professor at Paris-Est University in 1985, founded and directed a CNRS Laboratory on cell and tissue regeneration until 2003. He is now President of OTR3, Emeritus professor, honorary director CRRET CNRS unit and author in over 200 publications and 30 patents .

Biotechnology, Cell Biology, Cancer Research

Athanasios (Sakis) Mantalaris is Professor of BioSystems Engineering in the Department of Chemical Engineering at Imperial College London. He received his PhD (2000) in Chemical Engineering from the University of Rochester. His expertise is in modelling of biological systems and bioprocesses with a focus on mammalian cell culture systems, stem cell bioprocessing, and tissue engineering. He has published over 150 original manuscripts, co-edited one book, and holds several patents with several more pending. He has received several awards including the Junior Moulton Award for best paper by the Institute of Chemical Engineers (IChemE) in 2004. In 2012, he was elected Fellow of the American Institute for Medical & Biological Engineering and in 2013 he was awarded a European Research Council (ERC) Advanced Award. In 2015, he was awarded the Donal Medal by the Institution of Chemical Engineers (IChemE) for his contributions to biochemical engineering.

Stem cell bioprocessing, tissue engineering and mammalian cell bioprocessing.

Jane Lebkowski has been actively involved in the development of cell and gene therapies since 1986 and is currently Chief Scientific Officer and President of R&D at Asterias Biotherapeutics Inc, where she is responsible for all preclinical and product development of Asterias’ products. From 1998 to 2012, Dr. Lebkowski was Senior Vice President of Regenerative Medicine and Chief Scientific Officer at Geron Corporation. Dr. Lebkowski led Geron’s human embryonic stem cell program, being responsible for all research, preclinical development, product development, manufacturing, and clinical development activities. Prior to Geron, Dr. Lebkowski was Vice President of R&D at Applied Immune Sciences. Following acquisition of Applied Immune Sciences by Rhone Poulenc Rorer (currently Sanofi), Dr. Lebkowski served as Vice President of Discovery Research. Dr. Lebkowski received her Ph.D. in Biochemistry from Princeton University in 1982, and completed a postdoctoral fellowship at the Department of Genetics, Stanford University in 1986. Dr. Lebkowski has published over 70 peer reviewed papers and has 13 issued U.S. patents. Dr. Lebkowski is on the Board of Directors of the American Society for Gene and Cell Therapy. Dr Lebkowski also served as an industry representative to FDA’s Office of Cell, Tissue and Gene Therapy Advisory Board.

preclinical development, product development, manufacturing, and clinical development activities

Mary Mehrnoosh EshaghianWilner received a BS degree in Biomedical and Electrical Engineering 1985 MS degree in Computer Engineering 1985 Engineers degree in Electrical Engineering 1988 and PhD in Computer Engineering 1988 all from the University of Southern California USC. Dr Eshaghian Wilner is currently an Adjunct Professor of Electrical Engineering at the University of California Los Angeles UCLA. She is also a patent attorney admitted to the State Bar of California and the Washington DC Bar and is registered to practice before the United States Patent and Trademark Office.

Mary Mehrnoosh Eshaghian-Wilner is best known for her pioneering contributions to three areas of Optical Computing, Heterogeneous Computing, and Nano scale Computing. In the area of Optical Computing, she produced one of the first theses that dealt with the computational aspects of optical interconnects for VLSI chips.

Dennis M. Lox M.D. attended the University of Arizona where he was Phi Beta Kappa. Dr. Lox received his medical degree at the Texas Tech University Health Sciences Center, and his residency training in Physical Medicine and Rehabilitation at the University of Texas Health Sciences Center at San Antonio. Dr. Lox has maintained a private practice in the Tampa Bay, Florida area, and now in Beverly Hills, California. Dr Lox specializes in musculoskeletal disorders, sports medicine and Regenerative Medicine. Dr. Lox has edited two medical textbooks, written eight textbook chapters, and scientific publications. Dr. Lox has lectured extensively in the areas of Regenerative And Sports Medicine.

Lox has always pursued Sports Medicine, and this led to a path into Regenerative Medicine.

Esmaiel Jabbari completed his PhD at Purdue University and postdoctoral studies at Monsanto, Rice University, and Mayo Clinic. He is Full Professor of Chemical and Biomedical Engineering and Director of Biomimetic Materials and Tissue Engineering Laboratory at University of South Carolina. He is internationally known for his work on synthesis and processing of cell-responsive polymers and hydrogels for applications in regenerative medicine and growth factor delivery. He received the Berton Rahn Award from the AO Foundation in 2012 and the Stephen Milam Award from the Oral and Maxillofacial Surgery Foundation in 2008. He was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE) in 2013. He has published >200 books, book chapters, peer-reviewed journal articles, and conference proceedings, and presented >250 seminars at national and international conferences on biomaterials, tissue engineering, and drug delivery. He has mentored >100 visiting scholars, post-doctoral researchers, doctoral students, and undergraduate students. He is a member of numerous scientific organizations including BMES, SFB, TERMIS, MRS, EMBS, ACS, AIChE, and AACR.

Skeletal tissue engineering, Stem cell encapsulation and delivery, Self-assembled nanogels for growth factor delivery, Bioinspired materials, Multi‐scale composite materials, Drug targeting to cancer stem cells, Model gels to control cell microenvironment

Dr. Wang completed his MD in 1983 from Shandong Medical University and got his Postdoctoral studies in Danish Royal Hospital from 1990 to 1993. He is the director of Interventional Hospital of Shandong Red Cross Society, one of the top hospitals in China. He has published more than 20 papers in reputed journals and was awarded 7 national patents. He is the pioneer of stem cell therapy in the world, and has extensive collaborations with Harvard Medical School, University of Pennsylvania, etc. So far, Dr. Wang already performed several thousand clinical cases with stem cells during the past 12 years.

clinical cases with stem cells

Guillermo Estivill Torrús completed his PhD from University of Málaga (Spain) and postdoctoral studies from University of Edinburgh Medical School (UK). From 2002 he is the leader of the research group CTS643 “Applied Neuropsychopharmacology for Neurological and Neuropsychiatric diseases”. He is also Co-Principal Researcher of the research group "Neuroimmunology-Multiple Sclerosis" in the IBIMA, and Manager of the Image Unit (common support structures for research) in the same institution. More than 30 articles reflect his research concerning mostly the role of regulatory lipid molecules, mainly lysophosphatidic acid, on the central nervous system.

Neuroscience, Neurology

Petra Reinke's nephrologist and transplant physician. She leads since 2006 the research area immunology and cleanroom manufacturing facilities (GMP) on BCRT and is a member of the Steering Committee of the BCRT; since 2007 also a member of the steering committee of the Graduate School Berlin-Brandenburg School for Regenerative Therapies (BSRT). Petra Reinke engaged in their scientific work with the immunological processes and reactions during and after transplantation.

Transplant Medicine,Transplant Immunology, Immunology of Infection, Regenerative Medicine, cell therapy, immunopathogenesis of viral infection and allograft rejection

Gang Zheng, BSc (Hangzhou University), PhD (State University of New York at Buffalo), is Professor at the Department of Medical Biophysics (primary), the Leslie Dan Faculty of Pharmacy (cross), the Institute of Biomaterials and Biomedical Engineering (cross), University of Toronto. He is a Senior Scientist and the Joey and Toby Tanenbaum/Brazilian Ball Chair in Prostate Cancer Research at the Princess Margaret Cancer Center, and the Scientific Lead of Nanotechnology and Radiochemistry at the Techna Institute, UHN. He is also an Adjunct Professor of Radiology at the University of Pennsylvania. His primary research interests are nanomedicine, molecular imaging and phototherapy, with focus on clinically translatable technology to combat cancers. His recent porphysome discovery was named one of the “top 10 cancer breakthroughs of 2011” by the Canadian Cancer Society. He is currently leading a CIHR Team Grant on Nanomedicine and also leading the joint UHN/UofT effort in creating a CFI Nanomedicine Fabrication Center.

Nanomedicine Molecular imaging Phototherapy Image-guided intervention Porphyrins

Dr. Y. James Kang currently is a China National One-Thousand-Talents Professor and Director of the Regenerative Medicine Research Center at Sichuan University West China Medical College, the President and CEO of Sichuan 3D Bio-printing Institute; the Director of Sichuan Regenerative Medicine Research and Technology Center; the Editor-in-Chief of the journals Cardiovascular Toxicology and Regenerative Medicine Research; and the Editor of the book series of Methods in Pharmacology and Toxicology. Prior to his current positions, Dr. Kang was Professor and Distinguished University Scholar at University of Louisville, USA (1996-2009). He was elected as a fellow to the Academy of Toxicological Sciences in 2001.

His research interests are in regenerative medicine, focusing on 3D bio-printing and cardiovascular regeneration, as well as dietary manipulation of cardiovascular disease, liver fibrosis and cirrhosis, oxidative stress and antioxidant mechanisms, and non-human primate models for human diseases.

Vasiliki E. Kalodimou is Director of the Flow Cytometry-Research and Regenerative Medicine Department at IASO Maternity-Pediatric and Research Hospital in Athens, Greece. Before her current appointment, Kalodimou served as a haematology associate at General University Hospital of Heraklion, Crete, and as an instructor at both the General University Hospital of Heraklion and the Ipokratios Medical- Technical Institute of Athens. Kalodimou received her bachelor’s degree in Human Physiology and her master’s degree in Human Molecular Genetics from the Imperial College at the University of Medicine in London, UK. She completed her PhD at the University of Medicine in Athens, Greece, with an emphasis on stem cells and factors affecting their viability and absolute numbers.

Since 2006, Dr. Kalodimou has studied and working with stem cells from placenta, umbilical cord and adipose tissue, in every day practice and their applications in regenerative medicine and Flow Cytometry. Also is working in the area of human genetics & population genetics. In collaboration with the Hellenic Flow Cytometry Society, Kalodimou has developed quality control schemes for stem cell marker enumeration. The goal of this work is to find helpful new applications for flow cytometry, evaluate the risk factors for stem cell infusion, and improve the clarity and accessibility of measurements by flow cytometry. Her work quantifies and ranks all risks of flow cytometry enumeration to prevent and minimize the false-positive results from different cytometer uses. She is also working to establish combinations of monoclonal antibodies for mesenchymal and adipose tissue stem cell enumeration. In addition to collaboration with state universities and pharmaceutical companies on research projects, Kalodimou frequently publishes her findings. The Greek edition of the book was published in 2010 and has been well-received while in 2013 the English edition of the book was puplished by AABB Press USA. She is a member of two subsections of the AABB Cellular Therapies Section and also an AABB assessor.

Verdon Taylor is Professor of Embryology and Stem Cell Biology in the Department of Biomedicine of the University of Basel. His group studies neural stem cell maintenance and differentiation. Using genetic approaches, he addresses the signaling mechanisms that regulate neurogenesis during development and in the adult mammalian brain.

Development, Differentiation & Growth,Degenerative CNS Diseases,Stem cells and regeneration

Khalid Shah is an Associate Professor at Harvard Medical School and directs the Molecular Neurotherapy and Imaging Laboratory at Massachusetts General Hospital in Boston, MA. He is also the Director of the Stem Cell Therapeutics and Imaging program in MGH's Center for Translational Research, and is a Principal Faculty at Harvard Stem Cell Institute in Boston. Dr. Shah's recently published works are two books featuring current groundbreaking insights into stem cell therapies for cancer, Stem Cell Therapeutics for Cancer (Wiley-Blackwell 2013), and Mesenchymal Stem Cells in Cancer Therapy (Elsevier 2014). The potential of developing novel cancer therapies by him and his team has been recognized by many cancer alliances and associations. Based on this, he has received the young investigator award from Alliance for cancer gene therapy (ACGT), Research fellow award from American Cancer Society (ACS), Distinguished research award from Academy of Radiology and Innovation awards from James McDonnell Foundation, American Brain Tumor Association (ABTA) and Goldhirsh foundation. Additionally, Dr. Shah has participated in the training of numerous undergraduate, graduate students and residents at MGH and the potential of his mentoring has been recognized by Harvard Medical School, who recently awarded him the Harvard Young Mentor Award.

In recent years, Dr. Shah and his team have pioneered major developments in the cancer research field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology, validating the use of therapeutic stem cells alone and in combination with clinically approved drugs for cancer therapy.

Prof. Ludmila Buravkova (MD, PhD) - member of Russian Academy of Sciences, Head of Cell Physiology Lab, IBMP, professor of Moscow State University. She is an expert in stem cell and gravitational physiology, cell signaling, a tutor of 19 PhD students, has over 100 publications,12 patents, serves as editorial board Member of Human Physiology, Cell Technologies in Biology and Medicine, Advisory Boards in Russian Ministry of Science and Russian Found for Basic Research, PI of projects in cell physiology, has Award from Russian Government for Outstanding Scientific Results (2004), Award from Pleiades Publishing for best publications in Life Sciences (2014).

cell Technologies in Biology and Medicine

Xiushan Wu obtained his Ph.D. in Genetics from Stockholm University in 1990 and did postdoctoral studies in Developmental Biology at Michegan University, etc. during 1990-1994. He did research as a Scientist in Molecular Genetics at Karolinska Institute in 1994–2000. He is Professor and Director of The Center for Heart Development, Deputy Director of the Key Laboratory of the Ministry of Education of China for Developmental Biology and Protein Chemistry, at Hunan Normal University, China. His research focuses on understanding the mechanisms by which embryonic heart is developed using Drosophila, zebrafish and mice as models. He has published more than 300 papers (including over 100 papers in international journals).

The focus of our current research is to identify novel genes involved in heart development and to clarify the molecular mechanisms that lead to normal cardiac morphogenesis and function in vivo by generating transgenic and knockout flies, zebrafish and mice.

Gergana Dobreva did her PhD at the Gene Center, Ludwig Maximilian University, Munich, Germany, followed by a postdoc at the Gene Center and the Max Planck Institute of Immunobiology in Freiburg in the group of Prof. Rudolf Grosschedl. Her work during this period focused on the function of nuclear matrix attachment regions (MARs) and MAR-binding proteins in gene regulation. In 2006 she joined the group of Prof. Laugwitz at the Technical University, Munich as a postdoctoral fellow, working on the role of the LIM-domain transcription factor Isl1 during heart development. Since 2008 she is an Independent Scientific Research Group Leader, funded by the Emmy Noether Award from the Deutsche Forschungsgemeinschaft.

Cell biology, developmental biology, heart development, stem cells, epigenetics

Currently working as a Professor in the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.perienced in molecular biology and biochemistry studies in stem cells. The goal of my studies is to uncover the mechanism governing adult stem cell self renewal and differentiation.

The functions of PI3K, MAPK, and shh signaling in the maintenance and differentiation of muscle stem cells. The relationship between stem cell metabolism and their maintenance and differentiation. The effects of adipocytes on metabolism and differentiation potential of muscle progenitor cells, and the transdifferentiation between muscle progenitor cells and other cell types. Look for the progenitor of muscle stem cells, and compare the mechanisms governing embryonic muscle generation and adult muscle regeneration.

Currently working as a professoR in the Department of Ruminant Science, Institute of Animal Science Agricultural Research Organization.

Manipulating gene expression in the mammary gland of transgenic mice. Mammary gland biology. Transcription regulation of milk protein gene expression. The role of Stat5 in normal and malignant development. Translation mechanisms governing protein synthesis in the mammary gland. The role of amino acids and the mTOR pathway. Transgenic mouse model for breast cancer: Gene array and bioinformatical analyses of gene expression. Stem cells and cell hierarchy in the mammary gland.

Dr. Jyoti Bhojwani, is presently a Faculty of Genetics/Bioinformatics/ Principal Investigator of the M.Tech Research Programs (Bio-Informatics)at University of Indore, India. She obtained her B.Sc.(Bachelors degree) in Biological Sciences/Chemistry/Physics, M.Sc.(Master’s degree) in Life-Sciences, and Doctoral degree (Ph.D.) at School of Life-Sciences, University Of Indore. She pursued her post-doctoral ventures at Max-Planck Institute For Biophysical Chemistry (FRG), University Of California-Irvine and University Of Pittsburgh (USA). Currently, her projects mainly focus on translational-research and extrapolation of basic developmental mechanisms from model-systems like fruitfly (Drosophila) to human. Apart from this, her thrust areas of research interest include; Cancer Biology, Stem-Cell Biology and Homeotic-Gene Regulation. She is keen on studying in details the genetic factors, which presumably aid in understanding of mechanism by which “cancer stem cells” function in transforming a tissue from normal to cancerous states. Her research has a motive to further facilitate the perception of stem cell potential/mechanistic in areas of Regenerative Medicine, Translational Research and Anti-cancer therapy. Being involved in Clinical informatics, her students are also training a Cancer model and a Stem cell model, deploying Systems Biology approach and other Gene Networking BioInformatics tools. This novel area of research will hopefully lead to further understanding the tipping of balance from a stem cell/normal cell to a transformed cancer cell. Owing to her immense interest in science journalism and writing potential, she is now on the editorial board of four International Journals. Her Specialties Include: Research/Teaching/Mentoring/Science-Journalism

stem cell,regenarative medicine